Roche acquired Poseida Therapeutics as Poseida Therapeutics stock delisted

Roche acquired Poseida Therapeutics in a transaction announced on November 26, 2024, ending Poseida Therapeutics stock trading under PSTX. The terms included USD 9.00 in cash per share and a contingent value right worth up to USD 4.00 per share, according to Edgechat.

Roche terms set the benchmark

Multiples reported that the transaction implied an equity value of approximately USD 1.0 billion at closing and a potential total deal value of up to USD 1.5 billion when milestone payments are included. The USD 9.00 cash consideration represented a 215.00 percent premium to Poseida's November 25, 2024 closing price, according to Edgechat.

Cell therapies moved to Roche

Poseida developed allogeneic and autologous CAR-T candidates for hematologic cancers and solid tumors, alongside liver-directed gene therapies. Its platform used non-viral gene delivery and gene-editing technologies, while lead programs included therapies aimed at multiple myeloma and prostate cancer, according to the Poseida Therapeutics investor-relations page.

The strategic value for Roche lies in combining Poseida's cell-therapy candidates with Roche's global development and commercial infrastructure. The milestone structure also ties part of the transaction value to future program progress rather than assigning the full amount at closing.

PSTX status follows the transaction

Poseida was previously listed on Nasdaq under the ticker PSTX, with the acquisition transferring its programs and platform technologies into Roche's business. A company directory described the transaction as a December 2024 tender offer at USD 9.00 per share plus the contingent value right, according to SoCal.Startups.